SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19

To assess whether SARS-CoV-2-neutralising mAbs are effective and safe for treating patients with COVID-19 in comparison to an active comparator, placebo or no intervention, and to maintain the currency of the evidence, using a living systematic review approach.

A secondary objective is to track newly developing SARS-CoV-2-targeting mAbs from first tests in humans onwards.

This is a protocol.

Share/Save
Health topics: